DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Digital PCR and Real-time PCR Market by Technology (qPCR, dPCR), Product (Instrument, Reagent), Application (Oncology, Blood Testing, Pathogen Detection, Research, Forensic), End User (Hospital, Diagnostic Center, Academia, CRO) - Forecast to 2022" report to their offering.
The global dPCR and qPCR market is estimated to grow at a CAGR of 8.9% from 2017 to 2022, to reach USD 5.31 billion by 2022
The key factors driving the growth of this market include growth in the geriatric population, rising incidence of infectious diseases and genetic disorders, increasing investments and availability of funds for PCR-based research, and increasing use of biomarker profiling for disease diagnosis. However, factors such as high cost of dPCR products and technical limitations associated with qPCR and dPCR are restraining the growth of this market.
Based on the type of technology, the dPCR and qPCR market is classified into digital PCR (dPCR) and quantitative PCR (qPCR). In 2017, the qPCR technology segment is expected to account for the largest share of the market. However, the dPCR technology segment is expected to grow at the highest CAGR during the forecast period.
This growth can be attributed to the ongoing technological developments in dPCR, significant adoption of dPCR products among target end users, expansion of distribution networks of emerging dPCR product manufacturers, and growing private funding for the development and commercialization of innovative dPCR instruments.
The growth of this segment is mainly due to the procedural benefits of dPCR over qPCR, growing market demand for dPCR procedures (particularly in forensics and drug discovery), and rising number of dPCR-based researches across the globe.
Asia-Pacific to witness the highest growth during the forecast period (2017-2022).
- ABBott Laboratories
- Agilent Technologies Inc.
- Analytik Jena AG
- Becton, Dickinson and Company
- Bio-Rad Laboratories Inc.
- Biomeme Inc.
- Biomérieux S.A.
- Bioneer Corporation
- Biosystemika Research and Development LLC
- Danaher Corporation
- Denville Scientific Inc.
- Elitech Group
- Enzo Life Science Inc.
- Eppendorf AG
- F. Hoffmann-La Roche Ltd.
- Fluidigm Corporation
- Formulatrix Inc.
- Jn Medsys
- Merck KGaA
- Meridian Bioscience Inc.
- Promega Corporation
- Qiagen N.V.
- Quanta Biosciences Inc.
- Takara Bio Inc.
- Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/research/w4q8gg/digital_pcr_and